Tuesday, February 23, 2016

Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva

Reslizumab PDUFA action date is around the corner (March 30, 2016).
Reslizumab if approved could mean $1b in incremental sales for Teva by 2020.
At 10x 2015 Non-GAAP EPS, Valuation appears to discount the risks of failure.
Come March and investors in Teva (NYSE:TEVA) would keenly await the USFDA decision on its novel asthma biologic drug candidate reslizumab. Reslizumab PDUFA action date is in March 2016. Reslizumab acts through a same mechanism as GSK's Nucala (IL-5 inhibition) which was recently approved by the USFDA (November 4, 2015). Read More....